EGFR and non-small cell lung carcinoma: In an initial study, 11 patients with relapsed refractory non-small cell lung cancer (NSCLC) in which >50% tumour cells were EGFR+ were infused with up to 2.5 × 107 CAR T-cells/kg [34].